Exigência - art. 36 da LPI
#6.1
06/23/2026
RPI 2894
Application data
Number
112019005908Type
Filing
Publication
PCT
CN2017105410 The INPI issued a technical office action on this application. If it is not answered in time, the application is abandoned (art. 36 of the Brazilian IP Act).
Deadline to answer the office action:09/21/2026(27 days left)
Latest action published by the INPI: 06/23/2026. We update with every new RPI gazette, published weekly.
Applicants
JIANGSU HENGRUI MEDICINE CO.,LTD.
CN
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO., LTD.
CN
Inventors
C. Y. (pessoa física)
CN
G. C. (pessoa física)
CN
L. Z. (pessoa física)
CN
X. S. (pessoa física)
CN
Y. G. (pessoa física)
CN
IPC Classification
Priority claims
CN
201610884688.3 · 10/10/2016
Abstract
É revelado o uso de uma combinação de um anticorpo anti-PD-1 e um inibidor de VEGFR na preparação de um fármaco para tratamento de cânceres.
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.1
06/23/2026
RPI 2894
#6.1
01/27/2026
RPI 2873
#6.23
04/09/2024
RPI 2779
#15.35
10/05/2021
RPI 2648
#1.3
06/11/2019
RPI 2527
#1.1
04/02/2019
RPI 2517
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.